Loading…
Profound Medical Corp.
How the company evolved, year by year. Revenue and debt come from the annual reports — for most companies, the 10-K filings with the SEC since 2009; dividends from the payments themselves.
The bars are a balance on the closing date; the lines are what happened during the year. Revenue above equity is ordinary, not an anomaly — it means the company turns its capital over more than once a year.
Major managers that reported this stock in their latest 13F.
None of the investors we track reported a position in PROF.
▼ -57.4% over 5Y.
today you would have $393.44▼ -60.7%
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
The last 3 closed years. Each multiple uses that year’s closing price and that year’s reported numbers — not today’s. The range is set by the annual reports on record.
| Indicator | Median | 2025 | 2024 | 2023 |
|---|---|---|---|---|
| Year-end price | $7.87 | $7.51 | $8.49 | |
| P/E | 6.3x | 5.6x | 6.7x | 6.3x |
| P/S | 21.1x | 17.7x | 21.1x | 25.2x |
| P/B | 4.3x | 4.3x | 3.7x | 5.8x |
| EPS | $1.41 | $1.12 | $1.34 | |
| Profit margin | -264.44% |
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| BCYCBicycle Therapeutics PLC | $3.60 | — | 0.5x | — | -32.30% | $251.32M |
| SIONSionna Therapeutics, Inc. | $5.51 | — | 0.9x | — | -32.34% | $249.12M |
| IPHAInnate Pharma SA | $2.22 | — | — | — | — | $247.97M |
| ADAGAdagene Inc. | $3.68 |
Profound Medical Corp. operates as a commercial-stage medical device company that develops and markets AI-powered, MRI-guided, incision-free therapeutic systems for the image guided ablation of diseased tissue. The company's lead product TULSA-PRO system combines magnetic resonance imaging (MRI), robotically driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to ablate whole gland or physician defined region of malignant or benign prostate tissue. It also provides Sonalleve, which combines real-time MRI and thermometry for the treatment of uterine fibroids, adenomyotic tissue, palliative pain treatment of bone metastases, osteoid osteoma, and management of benign tumors. It operates in Canada, Germany, the United States, China, and Finland. Profound Medical Corp. is headquartered in Mississauga, Canada.
Company description provided by Yahoo Finance.
| -264.44% |
| -260.45% |
| -393.43% |
| ROE | -64.08% | -64.08% | -46.04% | -90.71% |
Median, not average: a single year of near-zero profit produces a P/E of 400 and would drag an average on its own. P/E years above 200x are left out, the same cut the fair price uses — so this median matches the “its own history” method below. Price and EPS have no median: they are series that grow.
| — |
| 2.8x |
| — |
| -28.50% |
| $247.09M |
| NGENNervgen Pharma Corp | $2.28 | — | 16.9x | — | -757.48% | $245.15M |
| ZNTLZentalis Pharmaceuticals, Inc. | $2.70 | — | 1.3x | — | -66.75% | $255.61M |